Breaking News, Collaborations & Alliances

Cellectar Partners with NorthStar for Ac-225 Supply

Aims to advance CLR 121225 into human clinical trials in 2025.

Author Image

By: Charlie Sternberg

Associate Editor

Cellectar Biosciences Inc. a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has signed a strategic supply agreement with NorthStar Medical Radioisotopes, LLC, for the procurement of NorthStar’s non-carrier added (n.c.a.) Ac-225.   Cellectar’s CLR 121225 development program combines its proprietary Phospholipid Ether (PLE) delivery platform and actinium 225 for the treatment of solid tumors, however...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters